Search Results - "Kwak, E.L"

Intraoperative Radiation Therapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiation Therapy for Pancreatic Adenocarcinoma by Keane, F.K, Wo, J.Y, Ferrone, C.R, Clark, J.W, Blaszkowsky, L.S, Allen, J.N, Kwak, E.L, Ryan, D.P, Lillemoe, K.D, Castillo, C. Fernandez-del, Hong, T.I

Get full text

Long-Term Outcomes and Toxicity of Anal Cancer Patients Treated Per Radiation Therapy Oncology Group 0529 by Mitra, D, Hong, T.I, Horick, N, Rose, B, Drapek, L.C, Blaszkowsky, L, Allen, J.N, Kwak, E.L, Murphy, J.E, Ryan, D.P, Cusack, J.C, Bordeianou, L, Berger, D.L, Wo, J.Y

Get full text

Influence of Body Mass Index (BMI) on Colorectal Cancer Mutation Status by Kamran, S.C, Russo, A.L, Borger, D.R, Szymonifka, J, Kwak, E.L, Clark, J.W, Blaszkowsky, L.S, Ryan, D.P, Allen, J.N, Wo, J.Y, Zhu, A.X, Iafrate, A, Haigis, K.M, Hong, T.S

Get full text

Clinical Predictors and Outcomes of Superior Mesenteric Vein or Portal Vein Thrombosis in the Setting of Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma by Keane, F.K, Wo, J.Y, Ferrone, C.R, Lillemoe, K.D, Clark, J, Blaszkowsky, L.S, Allen, J.N, Kwak, E.L, Ryan, D.P, Warshaw, A.L, Castillo, C. Fernandez-del, Hong, T.S

Get full text

484 Treatment of advanced solid tumors with golvatinib (E7050) in combination with lenvatinib (E7080) by Kwak, E.L, Juric, D, Cleary, J.M, Cote, G, Hilton, J.F, Flaherty, K.T, Wood, K, Rance, C, Barrett, S, Shapiro, G.I

Get full text

Clinical and Molecular Predictors of Local Failure After SBRT for Liver Metastases: A Secondary Analysis of a Prospective Phase II Trial by Wo, J.Y, Zhu, A.X, McDonnell, E.I, Yeap, B, Borger, D.R, Iafrate, A, Drapek, L.C, Blaszkowsky, L.S, Kwak, E.L, Clark, J, Goyal, L, Allen, J.N, Ryan, D.P, Arellano, R, Wolfgang, J.A, Mullen, J.T, Mamon, H.J, DeLaney, T.F, Hong, T.S

Get full text

A Single Arm Phase 2 Study of Individualized Proton-Based Stereotactic Body Radiation Therapy (P-SBRT) of Liver Metastases by Hong, T.S, Wo, J.Y, McDonnell, E.I, Yeap, B, Drapek, L.C, Wolfgang, J.A, Blaszkowsky, L.S, Kwak, E.L, Clark, J, Tanguturi, S, Goyal, L, Allen, J.N, Ryan, D.P, Arellano, R, Mullen, J.T, Mamon, H.J, DeLaney, T.F, Zhu, A.X

Get full text

354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer by Voss, M, Gordon, M.S, Mita, M, Rini, B, Makker, V, Macarulla, T, Smith, D, Kwak, E.L, Cervantes, A, Puzanov, I, Pili, R, Wang, D, Jalal, S, Pant, S, Patel, M, Neuwirth, R, Zohren, F, Infante, J

Get full text

Mutational Profile of Gastroesophageal Cancer Compared to Gastric and Esophageal Cancers by Russo, A.L, Kwak, E.L, Borger, D.R, Szymonifka, J, Mullen, J.T, Zhu, A.X, Blaszkowsky, L.S, Wo, J.Y, Ryan, D.P, Hong, T.S

Get full text

428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations by Corcoran, R, Coffee, E.M, van Allen, E, Ahronian, L.G, Wagle, N, Kwak, E.L, Faris, J.E, Iafrate, A.J, Garraway, L.A, Engelman, J.A

Get full text

Phase I clinical trial of intrahepatic arterial infusion of a HSV-1 replication-conditional mutant (rRRp450) by Ganguli, S, Oklu, R, Clark, J.W, Kwak, E.L, Kalva, S.P, Sahani, D, Blaszkowsky, L.S, Lawrence, D.P, Allen, J.N, Tanabe, K

Get full text

Long-term Outcomes of Neoadjuvant Chemotherapy (NC) before Chemoradiation (CRT) for Locally Advanced Pancreatic Cancer (LAPC) by Arvold, N.D, Ryan, D.P, Niemierko, A, Blaszkowsky, L.S, Kwak, E.L, Wo, J.Y, Allen, J.N, Wadlow, R.C, Fernandez-del Castillo, C, Hong, T.S

Get full text

Viral oncolytic therapy for liver metastases and primary liver tumors by Zurkiya, O, Ganguli, S, Oklu, R, Clark, J.W, Kwak, E.L, Kalva, S, Sahani, D, Blaszkowsky, L.S, Lawrence, D.P, Allen, J.N, Tanabe, K

Get full text

Phase I Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer by Wo, J.Y, Mamon, H.J, Ferrone, C.R, Ryan, D.P, Blaszkowsky, L.S, Kwak, E.L, Swanson, R.S, Lillemoe, K.D, Fernandez-Del Castillo, C, Hong, T.S

Get full text

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors by Haber, D A, Bell, D W, Sordella, R, Kwak, E L, Godin-Heymann, N, Sharma, S V, Lynch, T J, Settleman, J

“…Somatic mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are present in approximately 10% of non-small-cell lung cancer…”
Get full text

Pretreatment Tumor Size is Associated with Pathologic Complete Response to Preoperative Chemoradiation for Locally Advanced Rectal Adenocarcinoma by Russo, A.L, Wo, J.Y, Niemierko, A, Blaszkowsky, L.S, Mamon, H, Allen, J.N, Kwak, E.L, Wadlow, R.C, Ryan, D.P, Hong, T.S

Get full text

Phase I/II study of Proton-based Short Course Chemoradiation and Early Surgery for Adenocarcinoma of the Pancreas by Hong, T.S, Ryan, D.P, Blaszkowsky, L.S, Mamon, H.J, Wadlow, R.C, Kwak, E.L, Ferrone, C.R, Adams, J, Yeap, B, Winrich, B

Get full text

1417 POSTER A Phase II Trial of Afatinib (BIBW 2992) in Patients With Tumours Prospectively Screened for EGFR And/or HER2 Gene Amplification or EGFR Activating Mutations by Kwak, E.L, Shapiro, G.I, Cohen, S.M, Becerra, C.R, Lenz, H.J, Gooden, S, Robohn, M, Le-Maulf, F, Chand, V.K, lafrate, A.J

Get full text

G6 Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 by Kwak, E.L, Camidge, D.R, Clark, J, Shapiro, G.I, Maki, R.G, Ratain, M.J, Solomon, B, Bang, Y, Ou, S, Salgia, R

Get full text

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) by Solomon, B, Bang, Y.J, Camidge, D.R, Iafrate, A.J, Kwak, E.L, Maki, R.G, Ou, S.I, Salgia, R, Shaw, A, Clark, J

Get full text